Clinical Trial Update: A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of radium-223 dichloride with tasquinimod for bone-only metastatic castration-resistant prostate cancer has been with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Tasquinimod (tasquinimod)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC) | Phase 1 | Status: WITHDRAWN